Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was Not yet recruiting

Sponsor:

Information provided by:

Tel-Aviv Sourasky Medical Center

ClinicalTrials.gov Identifier:

NCT01089270

First received: March 17, 2010

Last updated: NA

Last verified: March 2010

History: No changes posted

Purpose

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.

Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.

The examination results will be given to the participants by a doctor from the neurology department.

Condition
Parkinson Disease

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective

Resource links provided by NLM:

Genetics Home Reference related topics: Parkinson disease Perry syndrome

MedlinePlus related topics: Movement Disorders Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment:	80
Study Start Date:	March 2010
Estimated Primary Completion Date:	March 2011 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	30 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

First degree relatives of diagnosed Parkinson patients that carry either LRRK2 or GBA gene mutation.

Ages: 30-80

Criteria

Inclusion Criteria:

healthy first degree relatives of diagnosed Parkinson patients

Exclusion Criteria:

patients unable to understand and sign an informed consent
minors
people with psychiatric disorders or a history of major head trauma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089270

Contacts

Contact: Einat Even-sapir, PhD, MD	972-3-6974444 ext 3536	evensap@tasmc.health.gov.il
Contact: Ayelet Kurzband, BA	972-3-6974444 ext 3536	ayeletk@tasmc.health.gov.il

Locations

Israel
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center	Not yet recruiting
Tel Aviv, Israel
Contact: Einat Even-Sapir, MD, PhD 972-3-6974444 ext 3536 Evensap@tasmc.health.gov.il
Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 ayeletk@tasmc.health.gov.il
Sub-Investigator: Hedva Lerman, MD
Sub-Investigator: Nir Giladi, PhD, MD
Sub-Investigator: Anat Milerman

Sponsors and Collaborators

Tel-Aviv Sourasky Medical Center

Investigators

Principal Investigator:

Einat Even-Sapir, MD, PhD

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

More Information

Publications:

Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R. Dopamine transporters decrease with age. J Nucl Med. 1996 Apr;37(4):554-9.

Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. Review.

Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. Review.

von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. Review.

Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. LRRK2 mutations in Parkinson disease. Neurology. 2005 Sep 13;65(5):738-40.

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007 Oct 16;69(16):1595-602.

Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69. Review.

Responsible Party:	Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine, Tel Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:	NCT01089270 History of Changes
Other Study ID Numbers:	TASMC-10-EES-0519-CTIL
Study First Received:	March 17, 2010
Last Updated:	March 17, 2010
Health Authority:	Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:

Parkinson
fdg pet-ct
i123 dat scan
first degree relatives of diagnosed Parkinson patients
with no clinical evidence of movement disorders

Additional relevant MeSH terms:

Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases

Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 16, 2013

To Top